Novel insights into vascularization patterns and angiogenic factors in glioblastoma subclasses
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Novel insights into vascularization patterns and angiogenic factors in glioblastoma subclasses
Authors
Keywords
Angiogenesis, Glioblastoma, Subclasses, Subtypes
Journal
JOURNAL OF NEURO-ONCOLOGY
Volume 131, Issue 1, Pages 11-20
Publisher
Springer Nature
Online
2016-09-16
DOI
10.1007/s11060-016-2269-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages
- (2016) Teresa E. Peterson et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival
- (2016) Jonas Kloepper et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial
- (2015) Thomas Sandmann et al. JOURNAL OF CLINICAL ONCOLOGY
- Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors
- (2015) Jeanette E. Eckel-Passow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial
- (2014) Walter Taal et al. LANCET ONCOLOGY
- A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
- (2014) Mark R. Gilbert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma
- (2014) Olivier L. Chinot et al. NEW ENGLAND JOURNAL OF MEDICINE
- Subclassification of Newly Diagnosed Glioblastomas through an Immunohistochemical Approach
- (2014) Siobhan Conroy et al. PLoS One
- Identifying the mesenchymal molecular subtype of glioblastoma using quantitative volumetric analysis of anatomic magnetic resonance images
- (2013) Kourosh M. Naeini et al. NEURO-ONCOLOGY
- Mechanisms of Glioma-Associated Neovascularization
- (2012) Matthew E. Hardee et al. AMERICAN JOURNAL OF PATHOLOGY
- Microarray Analysis Verifies Two Distinct Phenotypes of Glioblastomas Resistant to Antiangiogenic Therapy
- (2012) M. DeLay et al. CLINICAL CANCER RESEARCH
- Tumor-Initiating Cells of Various Tumor Types Exhibit Differential Angiogenic Properties and React Differently to Antiangiogenic Drugs
- (2012) Liat Benayoun et al. STEM CELLS
- Current concepts and management of glioblastoma
- (2011) Matthias Preusser et al. ANNALS OF NEUROLOGY
- EGFR-AKT-Smad Signaling Promotes Formation of Glioma Stem-like Cells and Tumor Angiogenesis by ID3-Driven Cytokine Induction
- (2011) X. Jin et al. CANCER RESEARCH
- EGFRvIII promotes glioma angiogenesis and growth through the NF-κB, interleukin-8 pathway
- (2011) R Bonavia et al. ONCOGENE
- Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1
- (2010) Roel G.W. Verhaak et al. CANCER CELL
- Molecular Therapeutic Targets for Glioma Angiogenesis
- (2010) Shingo Takano et al. Journal of Oncology
- Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
- (2009) Roger Stupp et al. LANCET ONCOLOGY
- Glioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1
- (2009) S. Zhao et al. SCIENCE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started